Genoa Pharmaceuticals has completed a $62 million Series A financing round to pursue a Phase 2 clinical trial of Aerodone (inhaled pirfenidone) to treat idiopathic pulmonary fibrosis (IPF). The Seattle-based company also appointed Dr. Ketan Patel, Dr. Naveed Siddiqi, Tiba Aynechi, Niall O’Donnell and Dr. Heather Preston to its board of directors. Dr. Jonathan Leff,…
News
New York scientists have created a mini-lung in a laboratory that mimics a real lung’s response to a viral infection in pulmonary fibrosis. The mini-lung, which scientists call an organoid, will increase understanding of lung diseases, leading to better treatments, the researchers said. Dr. Hans-Willem Snoeck, a professor at Columbia University…
Researchers have identified 39 genes as critical to idiopathic pulmonary fibrosis (IPF), based on a computational analysis of large genomic studies. Their study, “Detecting the Molecular System Signatures of Idiopathic Pulmonary Fibrosis through Integrated Genomic Analysis,” appeared in the journal Scientific Reports. IPF patients do not respond to anti-inflammatory therapies such…
Veracyte will present new information supporting the use of its genomic tests to diagnose idiopathic pulmonary fibrosis (IPF) and lung cancer at the American Thoracic Society 2017 International Conference in Washington, May 19-24. The Envisia and Percepta Bronchial Genomic Classifiers were designed to reduce the need for diagnostic surgery and to…
The anti-inflammatory molecule protectin DX (PDX) has been shown to improve pulmonary fibrosis (PF) and lung function in mice, new research shows. The study, “Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice,” was published in the journal Scientific Reports. Lung fibrosis is characterized…
Besides its other benefits, Esbriet (pirfenidone) prevents respiratory-related hospitalizations in patients with idiopathic pulmonary fibrosis (IPF), according to a study examining data from more than 1,200 patients. Findings also showed that hospitalized patients who took Esbriet were less likely to die after one year. This effect decreased over time, though researchers…
Proterris and Alfama recently announced a merger of the two companies which will effectively create the world’s leader in the field of carbon monoxide (CO) therapies for acute and chronic diseases, such as pulmonary fibrosis. “The merger of Alfama with Proterris represents a very synergistic and strategic fit between two…
Researchers have succeeded in growing tiny tissue structures in the lab that mirror the architecture of lungs, creating a model that opens new possibilities for researchers studying pulmonary fibrosis and other lung diseases. Although the research is still in early stages — with the tissue structures more resembling a fetal,…
INOpulse has shown promise in treating patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), concludes a study by Bellerophon Therapeutics, developer of the inhaled nitrous oxide device. The study, “Unraveling the Mode of Action of Pulsed Inhaled NO in Severe IPF Using Functional Respiratory Imaging.” showed that PH-IPF…
Left to right, Chicago Mayor Rahm Emanuel; Bill Vick, PF Warriors; Teresa Barnes, patient advocate; Tom Hurvis, Three Lakes Partners; Steven Collens, MATTER; and Ken Bahk, Three Lakes Partners. Photo Credit: Sean Su | CloudSpotter A group of philanthropists, medical-tech and business people have issued…
